Home News Teprotumumab efficacy sustained after 6 months in thyroid eye disease back to News
minute read
AUSTIN, Texas — In this Healio Video Perspective from the North American Neuro-Ophthalmology Society meeting, Prem Subramanian, MD, PhD, discusses the sustained efficacy of teprotumumab in patients with thyroid eye disease.
Topics: Press Coverage
1675 North Aurora Court
F731
Aurora, CO 80045
Administration: 720-848-2500
Appointments: 720-848-2020
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.
